Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNA-Doxorubicin in Cutaneous Squamous Cell Carcinoma
NCT05377905Phase 2Recruiting
- Start
- Sep 2023
- Primary completion
- Mar 2027
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin in cutaneous squamous cell carcinoma (cSCC). Started Sep 2023; status: recruiting.
02
Drugs
doxorubicin
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05377905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05377905.